Lucky No 5? Pharmacyclics collects $50mn for fifth patient in ibrutinib trial
This article was originally published in Scrip
Executive Summary
Five, or maybe 50, must be Pharmacyclics' lucky number: the Sunnyvale, California-based company collected a $50 million milestone payment from Janssen Biotech when the fifth patient was enrolled in the Phase III RESONATE clinical trial evaluating the partners' ibrutinib (PCI-32765) versus GlaxoSmithKline's Arzerra (ofatumumab) in patients with relapsed or refractory lymphocytic leukaemia or small lymphocytic lymphoma (CLL/SLL).